title: Fixed-dose combination of alogliptin/pioglitazone improves glycemic control in Japanese patients with type 2 diabetes mellitus independent of body mass index.
abstract: This study investigated the effects of switching from combination therapy with either alogliptin (Alo) or pioglitazone (Pio) to fixed-dose combination therapy (FDCT) with alogliptin and pioglitazone (Alo-Pio FDCT). The usefulness and efficacy of Alo-Pio FDCT were investigated. A total of 50 outpatients with type 2 diabetes mellitus (T2DM) treated with Alo and 47 outpatients with T2DM treated with Pio were switched to Alo-Pio FDCT, and its efficacy and usefulness were evaluated. Significant improvements were observed in hemoglobinA1c (HbA1c), alanine transaminase (ALT), and γ-glutamyl transpeptidase (GGT) levels after switching to Alo-Pio FDCT for 16 weeks in both groups. Only the group switching from Alo to Alo-Pio FDCT showed significant improvements in high-density lipoprotein cholesterol (HDL) levels and triglyceride levels. In a multivariate logistic regression model of the variation in the change of HbA1cat 16 weeks, ALT and GGT were independent predictors of the change of HbA1cat 16 weeks. In addition, the switch to Alo-Pio FDCT improved glycemic control to a certain degree regardless of BMI. Switching from either Alo or Pio to Alo-PIO FDCT may, unlike monotherapy with a DPP-4 inhibitor, be effective for patients with T2DM regardless of whether they are obese or lean.
authors.affiliation: Department of Endocrinology and Metabolism, Dokkyo Medical University, Shimotugagun, Japan.
authors.forename: Chie
authors.initials: C
authors.lastname: Aoki
authors.affiliation: Department of Endocrinology and Metabolism, Dokkyo Medical University, Shimotugagun, Japan.
authors.forename: Kunihiro
authors.initials: K
authors.lastname: Suzuki
authors.affiliation: Department of Endocrinology and Metabolism, Dokkyo Medical University, Shimotugagun, Japan; Green Clinic, Shimotugagun, Japan.
authors.forename: Hisamoto
authors.initials: H
authors.lastname: Kuroda
authors.affiliation: Department of Endocrinology and Metabolism, Dokkyo Medical University, Shimotugagun, Japan.
authors.forename: Masaaki
authors.initials: M
authors.lastname: Sagara
authors.affiliation: Department of Endocrinology and Metabolism, Dokkyo Medical University, Shimotugagun, Japan.
authors.forename: Masanori
authors.initials: M
authors.lastname: Shimizu
authors.affiliation: Ishibasi General Hospital, Shimotuke, Japan.
authors.forename: Kikuo
authors.initials: K
authors.lastname: Kasai
authors.affiliation: Department of Endocrinology and Metabolism, Dokkyo Medical University, Shimotugagun, Japan.
authors.forename: Yoshimasa
authors.initials: Y
authors.lastname: Aso
mesh_terms: D000368:Aged; D000410:Alanine Transaminase / Q000097:blood; D001786:Blood Glucose / Q000187:drug effects*; D015992:Body Mass Index; D008076:Cholesterol, HDL / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000627:therapeutic use; D005260:Female; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D000077205:Pioglitazone / Q000627:therapeutic use*; D010880:Piperidines / Q000627:therapeutic use*; D014498:Uracil / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005723:gamma-Glutamyltransferase / Q000097:blood
chemical_list: D000410:Alanine Transaminase; D001786:Blood Glucose; D008076:Cholesterol, HDL; D054873:Dipeptidyl-Peptidase IV Inhibitors; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D000077205:Pioglitazone; D010880:Piperidines; D014498:Uracil; D005723:gamma-Glutamyltransferase; C520853:alogliptin
keywords: alogliptin; dipeptidyl peptidase-4 inhibitor; fixed-dose combination therapy; pioglitazone; type 2 diabetes mellitus